BioScience Health Innovations I (BHIC): Financials
Trailing 12 months ended June 30, 2026
Income statement, cash flow and balance sheet figures for BioScience Health Innovations I (BHIC), read directly from the XBRL data the company files with the SEC. Over the trailing twelve months the company reported $4.5M of revenue, up 7.8% year over year. Net loss was $658.1K, or $-0.06 per diluted share. Gross margin stood at 53.8%.
Against the current share price, BHIC trades at 10.2 times trailing revenue.
7 fiscal years of history are available, back to 2020.
Frequently asked questions
How much revenue does BHIC make?
BioScience Health Innovations I reported $4.5M of revenue over the trailing twelve months, for the period ended June 30, 2026. That is up 7.8% from the same period a year earlier.
Is BHIC profitable?
BioScience Health Innovations I was unprofitable over the trailing twelve months, with a net loss of $658.1K.
Where does this financial data come from?
Every figure on this page is read from the company's own SEC 10-Q and 10-K filings. Nothing is estimated by a third party. Quarterly figures a company does not file separately (most commonly the fourth quarter) are derived by subtracting the reported year-to-date quarters from the full fiscal year, and are labelled as derived.
What is the difference between quarterly, annual and TTM?
Quarterly shows each three-month fiscal period on its own. Annual shows the full fiscal year as filed in the 10-K. TTM (trailing twelve months) sums the last four reported quarters, which is the most current annualised view between 10-K filings.